

## Data S1. Supplementary references

- Aarts MJ, Aerts JG, van den Borne BE, Biesma B, Lemmens VE and Kloover JS: Comorbidity in patients with small-cell lung cancer: Trends and prognostic impact. *Clin Lung Cancer* 16: 282-291, 2015.
- Abdel-Rahman O, Xu Y, Kong S, Dort J, Quan ML, Karim S, Bouchard-Fortier A, Cho H and Cheung WY: Impact of baseline cardiovascular comorbidity on outcomes in women with breast cancer: A real-world, population-based study. *Clin Breast Cancer* 19: e297-e305, 2019.
- Adejoro O, Alishahi A and Konety B: Association of comorbidity, age, and radical surgical therapy for prostate cancer, bladder cancer, and renal cell carcinoma. *Urology* 97: 130-137.e1, 2016.
- Ahern TP, Horváth-Puhó E, Spindler KL, Sørensen HT, Ording AG and Erichsen R: Colorectal cancer, comorbidity, and risk of venous thromboembolism: Assessment of biological interactions in a Danish nationwide cohort. *Br J Cancer* 114: 96-102, 2016.
- Alwhaibi M, AlRuthia Y, Alhawassi TM, Almalag H, Alsalloum H and Balkhi B: Polypharmacy and comorbidities among ambulatory cancer patients: A cross-sectional retrospective study. *J Oncol Pharm Pract* 26: 1052-1059, 2020.
- Arguello-Guerra L, Vargas-Chandomid E, Díaz-González JM, Méndez-Flores S, Ruelas-Villavicencio A and Domínguez-Cherit J: Incidence of complications in dermatological surgery of melanoma and non-melanoma skin cancer in patients with multiple comorbidity and/or antiplatelet-anticoagulants. Five year experience in our Hospital. *Cir Cir* 86: 15-23, 2019.
- Backes FJ, Rosen M, Liang M, McCann GA, Clements A, Cohn DE, O'Malley DM, Salani R and Fowler JM: Robotic hysterectomy for endometrial cancer in obese patients with comorbidities: Evaluating postoperative complications. *Int J Gynecol Cancer* 25: 1271-1276, 2015.
- Bar D, Lavie O, Stein N, Feferkorn I and Shai A: The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer. *Eur J Obstet Gynecol Reprod Biol* 207: 227-231, 2016.
- Baretti M, Rimassa L, Personeni N, Giordano L, Tronconi MC, Pressiani T, Bozzarelli S and Santoro A: Effect of comorbidities in stage II/III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single-center, observational study. *Clin Colorectal Cancer* 17: e489-e498, 2018.
- Beckmann K, Garmo H, Adolfsen J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P and Van Hemelrijck M: Androgen deprivation therapies and changes in comorbidity: A comparison of gonadotropin-releasing hormone agonists and antiandrogen monotherapy as primary therapy in men with high-risk prostate cancer. *Eur Urol* 75: 676-683, 2019.
- Belot A, Fowler H, Njagi EN, Luque-Fernandez MA, Maringe C, Magadi W, Exarchakou A, Quaresma M, Turculet A, Peake MD, *et al*: Association between age, deprivation and specific comorbid conditions and the receipt of major surgery in patients with non-small cell lung cancer in England: A population-based study. *Thorax* 74: 51-59, 2019.
- Bernardi D, Asti E, Aiolfi A, Bonitta G, Luporini A and Bonavina L: Outcome of trimodal therapy in elderly patients with esophageal cancer: Prognostic value of the Charlson comorbidity index. *Anticancer Res* 38: 1815-1820, 2018.
- Binder PS, Peipert JF, Kallogjeri D, Brooks RA, Massad LS, Mutch DG, Powell MA, Thaker PH and McCourt CK: Adult comorbidity evaluation 27 score as a predictor of survival in endometrial cancer patients. *Am J Obstet Gynecol* 215: 766.e1-766.e9, 2016.
- Boakye D, Rillmann B, Walter V, Jansen L, Hoffmeister M and Brenner H: Impact of comorbidity and frailty on prognosis in colorectal cancer patients: A systematic review and meta-analysis. *Cancer Treat Rev* 64: 30-39, 2018.
- Boakye D, Walter V, Jansen L, Martens UM, Chang-Claude J, Hoffmeister M and Brenner H: Magnitude of the age-advance-ment effect of comorbidities in colorectal cancer prognosis. *J Natl Compr Canc Netw* 18: 59-68, 2020.
- Bollig C, Ahmad J and Dooley L: Effect of medical comorbidities on treatment regimen and survival in T3/T4 laryngeal cancer. *Laryngoscope* 130: 1459-1464, 2020.
- Cao KI, Salvati F, Laki F, Falcou MC, Carton M, Poortmans P, Fourquet A and Kirova YM: Outcomes of postoperative radiation therapy for breast cancer in older women according to age and comorbidity status: An observational retrospective study in 752 patients. *J Geriatr Oncol* 9: 600-605, 2018.
- Cao KI, Waechter L, Carton M and Kirova YM: Outcomes of exclusive radiation therapy for older women with breast cancer according to age and comorbidity status: An observational retrospective study. *Breast J* 26: 976-980, 2020.
- Caparrotti F, O'Sullivan B, Bratman SV, Ringash J, Lu L, Bayley A, Cho J, Giuliani M, Hope A, Kim J, *et al*: Exploring the impact of human papillomavirus status, comorbidity, polypharmacy, and treatment intensity on outcome of elderly oropharyngeal cancer patients treated with radiation therapy with or without chemotherapy. *Int J Radiat Oncol Biol Phys* 98: 858-867, 2017.
- Chen R, Ryan P, Natarajan K, Falconer T, Crew KD, Reich CG, Vashisht R, Randhawa G, Shah NH and Hripcsak G: Treatment patterns for chronic comorbid conditions in patients with cancer using a large-scale observational data network. *JCO Clin Cancer Inform* 4: 171-183, 2020.
- Chen YG, Pan HH, Dai MS, Lin C, Lu CS, Su SL, Chang PY, Huang TC, Chen JH, Wu YY, *et al*: Impact of comorbidity and age on determinants therapeutic strategies in advanced pancreatic head cancer patients with obstructive jaundices. *Medicine (Baltimore)* 94: e1298, 2015.
- Connor KL, Pattie S, Kerr GR and Junor E: Treatment, comorbidity and survival in stage III laryngeal cancer. *Head Neck* 37: 698-706, 2015.
- Criss SD, Palazzo L, Watson TR, Paquette AM, Sigel K, Wisnivesky J and Kong CY: Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden. *PLoS One* 15: e0228288, 2020.
- Currie AC, Askari A, Rao C, Saunders BP, Athanasiou T, Faiz OD and Kennedy RH: The potential impact of local excision for T1 colonic cancer in elderly and comorbid populations: A decision analysis. *Gastrointest Endosc* 84: 986-994, 2016.
- Cuthbert CA, Hemmelgarn BR, Xu Y and Cheung WY: The effect of comorbidities on outcomes in colorectal cancer survivors: A population-based cohort study. *J Cancer Surviv* 12: 733-743, 2018.
- Dalton SO, Steding-Jessen M, Jakobsen E, Mellemgaard A, Østerlind K, Schütz J and Johansen C: Socioeconomic position and survival after lung cancer: Influence of stage, treatment and comorbidity among Danish patients with lung cancer diagnosed in 2004-2010. *Acta Oncol* 54: 797-804, 2015.
- Daskivich TJ, Dru CJ, Skarecky D, Ahlering T and Freedland SJ: Association of comorbid disease burden at diagnosis with higher tumor grade in men with non-metastatic prostate cancer. *Prostate Cancer Prostatic Dis* 20: 343-347, 2017.
- Daskivich TJ, Thomas IC, Luu M, Shelton JB, Makarov DV, Skolarus TA and Leppert JT: External validation of the prostate cancer specific comorbidity index: A claims based tool for the prediction of life expectancy in men with prostate cancer. *J Urol* 202: 518-524, 2019.
- de Boer AZ, van der Hulst HC, de Glas NA, Marang-van de Mheen PJ, Siesling S, de Munck L, de Ligt KM, Portielje JEA, Bastiaannet E and Liefers GJ: Impact of older age and comorbidity on locoregional and distant breast cancer recurrence: A large population-based study. *Oncologist* 25: e24-e30, 2020.
- DeWees TA, Nikitas J, Rehman S, Bradley JD, Robinson CG and Roach MC: Defining optimal comorbidity measures for patients with early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. *Pract Radiat Oncol* 9: e83-e89, 2019.
- Diaz A, Baade PD, Valery PC, Whop LJ, Moore SP, Cunningham J, Garvey G, Brotherton JML, O'Connell DL, Canfell K, *et al*: Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012). *PLoS One* 13: e0196764, 2018.
- Dilley S, Erickson BK, Phillips CE, Kennemer CR, Zhang B, Martin T, Martin JY, Shah MM, Michael Straughn J Jr and Leath CA III: Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer? *Gynecol Oncol* 149: 49-52, 2018.
- Dima S, Chen KH, Wang KJ, Wang KM and Teng NC: Effect of comorbidity on lung cancer diagnosis timing and mortality: A nationwide population-based cohort study in Taiwan. *Biomed Res Int* 2018: 1252897, 2018.
- Dobbins TA, Badgery-Parker T, Currow DC and Young JM: Assessing measures of comorbidity and functional status for risk adjustment to compare hospital performance for colorectal cancer surgery: A retrospective data-linkage study. *BMC Med Inform Decis Mak* 15: 55, 2015.

35. Dreyer J, Bremer M and Henkenberens C: Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer. *Radiat Oncol* 13: 213, 2018.
36. Drzayich Antol D, Waldman Casebeer A, Khoury R, Michael T, Renda A, Hopson S, Parikh A, Stein A, Costantino M, Stenkowski S and Bunce M: The relationship between comorbidity medication adherence and health related quality of life among patients with cancer. *J Patient Rep Outcomes* 2: 29, 2018.
37. Efrid JT, Hunter S, Chan S, Jeong S, Thomas SL, Jindal C and Biswas T: The association between age, comorbidities and use of radiotherapy in women with breast cancer: Implications for survival. *Medicines (Basel)* 5: 62, 2018.
38. Emerson MA, Banegas MP, Chawla N, Achacoso N, Alexeeff SE, Adams AS and Habel LA: Disparities in prostate, lung, breast, and colorectal cancer survival and comorbidity status among urban American Indians and Alaskan Natives. *Cancer Res* 77: 6770-6776, 2017.
39. Ess SM, Herrmann C, Bouchardy C, Neyroud I, Rapiti E, Konzelmann I, Bordoni A, Ortelli L, Rohrmann S, Frick H, *et al*: Impact of subtypes and comorbidities on breast cancer relapse and survival in population-based studies. *Breast* 41: 151-158, 2018.
40. Ewertz M, Land LH, Dalton SO, Cronin-Fenton D and Jensen MB: Influence of specific comorbidities on survival after early-stage breast cancer. *Acta Oncol* 57: 129-134, 2018.
41. Eytan DF, Blackford AL, Eisele DW and Fakhry C: Prevalence of comorbidities among older head and neck cancer survivors in the United States. *Otolaryngol Head Neck Surg* 160: 85-92, 2019.
42. Faiz Z, van Putten M, Verhoeven RHA, van Sandick JW, Nieuwenhuijzen GAP, van der Sangen MJC, Lemmens VEPP, Wijnhoven BPL and Plukker JTM: Impact of age and comorbidity on choice and outcome of two different treatment options for patients with potentially curable esophageal cancer. *Ann Surg Oncol* 26: 986-995, 2019.
43. Fiorentino A, Mazzola R, Gaj Levra N, Fersino S, Ricchetti F, Di Paola G, Gori S, Massocco A and Alongi F: Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients. *Aging Clin Exp Res* 30: 533-538, 2018.
44. Froehner M, Koch R, Hubler M and Wirth MP: Validation of an age-adjusted prostate cancer-specific comorbidity index. *Eur Urol* 69: 764-766, 2016.
45. Genther DJ and Gourin CG: Effect of comorbidity on short-term outcomes and cost of care after head and neck cancer surgery in the elderly. *Head Neck* 37: 685-693, 2015.
46. Gollnitz I, Inhestern J, Wendt TG, Buentzel J, Esser D, Böger D, Mueller AH, Piesold JU, Schultze-Mosgau S, Eigendorff E, *et al*: Role of comorbidity on outcome of head and neck cancer: A population-based study in Thuringia, Germany. *Cancer Med* 5: 3260-3271, 2016.
47. Gottlieb M, Marsaa K, Godtfredsen NS and Mellemgaard A: Prevalence and management of pulmonary comorbidity in patients with lung and head and neck cancer. *Acta Oncol* 54: 767-771, 2015.
48. Gould MK, Munoz-Plaza CE, Hahn EE, Lee JS, Parry C and Shen E: Comorbidity profiles and their effect on treatment selection and survival among patients with lung cancer. *Ann Am Thorac Soc* 14: 1571-1580, 2017.
49. Grønhøj C, Kronberg Jakobsen K, Kjær E, Friberg J and von Buchwald C: Comorbidity in HPV+ and HPV- oropharyngeal cancer patients: A population-based, case-control study. *Oral Oncol* 96: 1-6, 2019.
50. Guiriguet C, Pera G, Castells A, Toran P, Grau J, Rivero I, Buron A, Macià F, Vela-Vallespín C, Vilarrubí-Estrella M and Marzo-Castillejo M: Impact of comorbid conditions on participation in an organised colorectal cancer screening programme: A cross-sectional study. *BMC Cancer* 17: 524, 2017.
51. Guldborg TL, Christensen S, Zachariae R and Jensen AB: Prognostic factors in early breast cancer associated with body mass index, physical functioning, physical activity, and comorbidity: Data from a nationwide Danish cohort. *Breast Cancer Res Treat* 162: 159-167, 2017.
52. Gurney J, Sarfati D and Stanley J: The impact of patient comorbidity on cancer stage at diagnosis. *Br J Cancer* 113: 1375-1380, 2015.
53. Hah YS, Lee KS, Choi IY, Lee JY, Hong JH, Kim CS, Lee HM, Hong SK, Byun SS, Lee SH, *et al*: Effects of age and comorbidity on survival vary according to risk grouping among patients with prostate cancer treated using radical prostatectomy: A retrospective competing-risk analysis from the K-CaP registry. *Medicine (Baltimore)* 97: e12766, 2018.
54. Hahn EE, Gould MK, Munoz-Plaza CE, Lee JS, Parry C and Shen E: Understanding comorbidity profiles and their effect on treatment and survival in patients with colorectal cancer. *J Natl Compr Canc Netw* 16: 23-34, 2018.
55. Hamakawa T, Kurokawa Y, Mikami J, Miyazaki Y, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Mori M and Doki Y: Risk factors for postoperative complications after gastrectomy in gastric cancer patients with comorbidities. *Surg Today* 46: 224-228, 2016.
56. Hang J, Cai B, Xue P, Wang L, Hu H, Zhou Y, Ren S, Wu J, Zhu M, Chen D, *et al*: The joint effects of lifestyle factors and comorbidities on the risk of colorectal cancer: A large Chinese retrospective case-control study. *PLoS One* 10: e0143696, 2015.
57. Heo J, Chun M, Oh YT, Noh OK and Kim L: Metabolic comorbidities and medical institution utilization among breast cancer survivors: A national population-based study. *Korean J Intern Med* 35: 421-428, 2020.
58. Hsieh MC, Thompson T, Wu XC, Styles T, O'Flarity MB, Morris CR and Chen VW: The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients. *Cancer Med* 5: 871-880, 2016.
59. Huang Y, Chen W, Haque W, Verma V, Xing Y, The BS and Brian Butler E: The impact of comorbidity on overall survival in elderly nasopharyngeal carcinoma patients: A national cancer data base analysis. *Cancer Med* 7: 1093-1101, 2018.
60. Ibfelt EH, Dalton SO, Hogdall C, Fagö-Olsen CL, Steding-Jessen M, Osler M, Johansen C, Frederiksen K and Kjær SK: Do stage of disease, comorbidity or access to treatment explain socioeconomic differences in survival after ovarian cancer? -A cohort study among Danish women diagnosed 2005-2010. *Cancer Epidemiol* 39: 353-359, 2015.
61. Islam KM, Jiang X, Anggondowati T, Lin G and Ganti AK: Comorbidity and survival in lung cancer patients. *Cancer Epidemiol Biomarkers Prev* 24: 1079-1085, 2015.
62. Iwai N, Dohi O, Naito Y, Inada Y, Fukui A, Takayama S, Ogita K, Terasaki K, Nakano T, Ueda T, *et al*: Impact of the Charlson comorbidity index and prognostic nutritional index on prognosis in patients with early gastric cancer after endoscopic submucosal dissection. *Dig Endosc* 30: 616-623, 2018.
63. Jeffery DD, Art Ambrosio L, Hopkins L and Burke HB: Mental health comorbidities and cost/utilization outcomes in head and neck cancer patients. *J Psychosoc Oncol* 37: 301-318, 2019.
64. Jeong J, Jeong MJ, Choi K, Kim MJ, Han Y, Kwon TW and Cho YP: Clinical outcomes of comorbid cancer patients with venous thromboembolism: A retrospective, single-center study in Korea. *Medicine (Baltimore)* 98: e17181, 2019.
65. Jespersen CG, Nørsgaard M, Jacobsen JB and Borre M: Patient comorbidity is associated with conservative treatment of localized prostate cancer. *Scand J Urol* 49: 366-370, 2015.
66. Johnston GM, Urquhart R, Lethbridge L and MacIntyre M: Increasing our understanding of dying of breast cancer: Comorbidities and care. *Prog Palliat Care* 24: 147-152, 2016.
67. Jones SM, Rosenberg D, Ludman E and Arterburn D: Medical comorbidity and psychotropic medication fills in older adults with breast or prostate cancer. *Support Care Cancer* 23: 3005-3009, 2015.
68. Kahl A, du Bois A, Harter P, Prader S, Schneider S, Heitz F, Traut A, Alesina PF, Meier B, Walz M, *et al*: Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. *Ann Surg Oncol* 24: 3692-3699, 2017.
69. Kasten KR, Celio AC, Trakimas L, Manwaring ML and Spaniolas K: Trainee-associated outcomes in laparoscopic colectomy for cancer: Propensity score analysis accounting for operative time, procedure complexity and patient comorbidity. *Surg Endosc* 32: 702-711, 2018.
70. Kato M, Nishida T, Hamasaki T, Kawai N, Yoshio T, Egawa S, Yamamoto K, Ogiyama H, Komori M, Nakahara M, *et al*: Outcomes of ESD for patients with early gastric cancer and comorbid liver cirrhosis: A propensity score analysis. *Surg Endosc* 29: 1560-1566, 2015.



71. Keshtgarpour M, Tan WS, Zwanziger J, Awadalla S, Langi FG and Dudek AZ: Prognostic value of serum proteomic test and comorbidity index in diversified population with lung cancer. *Anticancer Res* 36: 1759-1765, 2016.
72. Kimmick GG, Li X, Fleming ST, Sabatino SA, Wilson JF, Lipscomb J, Cress R, Bergom C, Anderson RT and Wu XC: Written on behalf of the Center for Disease Control and Prevention National Program of Cancer Registry Patterns of Care Study Group: Risk of cancer death by comorbidity severity and use of adjuvant chemotherapy among women with locoregional breast cancer. *J Geriatr Oncol* 9: 214-220, 2018.
73. Koeter T, van Elderen SGC, van Tilborg GFAJB, de Wilt JHW, Wasowicz DK, Rozema T and Zimmerman DDE: MRI response rate after short-course radiotherapy on rectal cancer in the elderly comorbid patient: Results from a retrospective cohort study. *Radiat Oncol* 15: 53, 2020.
74. Krarup PM, Nordholm-Carstensen A, Jorgensen LN and Harling H: Association of comorbidity with anastomotic leak, 30-day mortality, and length of stay in elective surgery for colonic cancer: A nationwide cohort study. *Dis Colon Rectum* 58: 668-676, 2015.
75. Kurnit KC, Ward KK, McHale MT, Saenz CC and Plaxe SC: Increased prevalence of comorbid conditions in women with uterine cancer. *Gynecol Oncol* 138: 731-734, 2015.
76. Kuwada K, Kuroda S, Kikuchi S, Yoshida R, Nishizaki M, Kagawa S and Fujiwara T: Sarcopenia and comorbidity in gastric cancer surgery as a useful combined factor to predict eventual death from other causes. *Ann Surg Oncol* 25: 1160-1166, 2018.
77. Lee BO, Choi WJ, Sung NY, Lee SK, Lee CG and Kang JI: Incidence and risk factors for psychiatric comorbidity among people newly diagnosed with cancer based on Korean national registry data. *Psychooncology* 24: 1808-1814, 2015.
78. Lee CC, Ho HC, Su YC, Chen PC, Yu CH and Yang CC: Comparison of different comorbidity measures for oral cancer patients with surgical intervention: A longitudinal study from a single cancer center. *Auris Nasus Larynx* 43: 322-329, 2016.
79. Lembicz M, Gabryel P, Brajer-Luftmann B, Dyszkiewicz W and Batura-Gabryel H: Comorbidities with non-small cell lung cancer: Is there an interdisciplinary consensus needed to qualify patients for surgical treatment? *Ann Thorac Med* 13: 101-107, 2018.
80. Lichtensztajn DY, Giddings BM, Morris CR, Parikh-Patel A and Kizer KW: Comorbidity index in central cancer registries: The value of hospital discharge data. *Clin Epidemiol* 9: 601-609, 2017.
81. Lin J, McGlynn KA, Nations JA, Shriver CD and Zhu K: Comorbidity and stage at diagnosis among lung cancer patients in the US military health system. *Cancer Causes Control* 31: 255-261, 2020.
82. Linden S, Redig J, Banos Hernaez A, Nilsson J, Bartels DB and Justo N: Comorbidities and relevant outcomes, commonly associated with cancer, of patients newly diagnosed with advanced non-small-cell lung cancer in Sweden. *Eur J Cancer Care (Engl)* 29: e13171, 2020.
83. Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Ke J and Kelsh MA: Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. *J Gastrointest Cancer* 47: 168-181, 2016.
84. Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, Rebbeck TR, Chapman A, Kantoff PW, Cullen J, *et al*: Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. *Eur Urol* 77: 158-166, 2020.
85. Lubeck SFK, Michielsens CAJ, Borgonjen RJ, Bronkhorst EM, van de Kerkhof PCM and Gerritsen MP: Impact of high age and comorbidity on management decisions and adherence to guidelines in patients with keratinocyte skin cancer. *Acta Derm Venereol* 97: 825-829, 2017.
86. Luchtenborg M, Morris EJA, Tataru D, Coupland VH, Smith A, Milne RL, Te Marvelde L, Baker D, Young J, Turner D, *et al*: Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer. *Thorax* 73: 339-349, 2018.
87. Lunardi P, Ploussard G, Grosclaude P, Roumiguié M, Soulié M, Beauval JB and Malavaud B: Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk. *World J Urol* 35: 587-593, 2017.
88. Luo L, Du W, Chong S, Ji H and Glasgow N: Patterns of comorbidities in hospitalised cancer survivors for palliative care and associated in-hospital mortality risk: A latent class analysis of a statewide all-inclusive inpatient data. *Palliat Med* 33: 1272-1281, 2019.
89. Manderbacka K, Arffman M, Suvisaari J, Ahlgren-Rimpiläinen A, Lumme S, Keskimäki I and Pukkala E: Effect of stage, comorbidities and treatment on survival among cancer patients with or without mental illness. *Br J Psychiatry* 211: 304-309, 2017.
90. Maringe C, Fowler H, Rachet B and Luque-Fernandez MA: Reproducibility, reliability and validity of population-based administrative health data for the assessment of cancer non-related comorbidities. *PLoS One* 12: e0172814, 2017.
91. Media AS, Persson M, Tajhizi N and Weinreich UM: Chronic obstructive pulmonary disease and comorbidities' influence on mortality in non-small cell lung cancer patients. *Acta Oncol* 58: 1102-1106, 2019.
92. Mehta HB, Sura SD, Adhikari D, Andersen CR, Williams SB, Senagore AJ, Kuo YF and Goodwin JS: Adapting the Elixhauser comorbidity index for cancer patients. *Cancer* 124: 2018-2025, 2018.
93. Minicozzi P, Van Eycken L, Molinie F, Innos K, Guevara M, Marcos-Gragera R, Castro C, Rapiti E, Katalinic A, Torrella A, *et al*: Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer. *Int J Cancer* 144: 2118-2127, 2019.
94. Minicozzi P, Vicentini M, Innos K, Castro C, Guevara M, Stracci F, Carmona-Garcia M, Rodriguez-Barranco M, Vanschoenbeek K, Rapiti E, *et al*: Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study. *Eur J Surg Oncol* 46: 1151-1159, 2020.
95. Mohammadi M, Cao Y, Glimelius I, Bottai M, Eloranta S and Smedby KE: The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma—a Swedish population-based study. *BMC Cancer* 15: 850, 2015.
96. Morishima T, Matsumoto Y, Koeda N, Shimada H, Maruhama T, Matsuki D, Nakata K, Ito Y, Tabuchi T and Miyashiro I: Impact of comorbidities on survival in gastric, colorectal, and lung cancer patients. *J Epidemiol* 29: 110-115, 2019.
97. Murawski M, Walter J and Schwarzkopf L: Assessing the lung cancer comorbidome: An analysis of German claims data. *Lung Cancer* 127: 122-129, 2019.
98. Nadaraja S, Jørgensen TL, Matzen L and EHerrstedt J: Impact of age, comorbidity, and FIGO stage on treatment choice and mortality in older Danish patients with gynecological cancer: A retrospective register-based cohort study. *Drugs Real World Outcomes* 5: 225-235, 2018.
99. Ng HS, Koczwara B, Roder D and Vitry A: Changes in the prevalence of comorbidity in the Australian population with cancer, 2007-2014. *Cancer Epidemiol* 54: 56-62, 2018.
100. Ng HS, Vitry A, Koczwara B, Roder D and McBride ML: Patterns of comorbidities in women with breast cancer: A Canadian population-based study. *Cancer Causes Control* 30: 931-941, 2019.
101. Niazi SK, Naessens JM, White L, Borah B, Vargas ER, Richards J, Cabral S, Clark MM and Rummans T: Impact of psychiatric comorbidities on health care costs among patients with cancer. *Psychosomatics* 61: 145-153, 2020.
102. Nilsson J, Berglund A, Bergström S, Bergqvist M and Lambe M: The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: A population-based study. *Acta Oncol* 56: 949-956, 2017.
103. Nishikawa T, Kawai K, Emoto S, Muroto K, Hiyoshi M, Kaneko M, Sonoda H, Sasaki K, Shuno Y, Tanaka T, *et al*: The influence of pulmonary comorbidities on treatment choice and short-term surgical outcomes among elderly patients with colorectal cancer. *Int J Colorectal Dis* 34: 1497-1501, 2019.
104. Noer MC, Antonsen SL, Ottesen B, Christensen IJ and Høgdall C: Type I versus type II endometrial cancer: Differential impact of comorbidity. *Int J Gynecol Cancer* 28: 586-593, 2018.
105. Noer MC, Leandersson P, Paulsen T, Rosthøj S, Antonsen SL, Borgfeldt C and Høgdall C: Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients—a comparative cohort study. *Acta Oncol* 57: 1100-1108, 2018.
106. Noer MC, Sperling CD, Antonsen SL, Ottesen B, Christensen IJ and Høgdall C: A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients. *Gynecol Oncol* 141: 471-478, 2016.
107. Noer MC, Sperling CD, Ottesen B, Antonsen SL, Christensen IJ and Høgdall C: Ovarian cancer and comorbidity: Is poor survival explained by choice of primary treatment or system delay? *Int J Gynecol Cancer* 27: 1123-1133, 2017.

108. Ording AG, Horváth-Puhó E, Lash TL, Ehrenstein V, Borre M, Vyberg M and Sørensen HT: Prostate cancer, comorbidity, and the risk of venous thromboembolism: A cohort study of 44,035 Danish prostate cancer patients, 1995-2011. *Cancer* 121: 3692-3699, 2015.
109. Ording AG, Horváth-Puhó E, Lash TL, Ehrenstein V, Borre M, Vyberg M and Sørensen HT: Does comorbidity interact with prostate cancer to increase mortality? A Danish cohort study of 45 326 prostate cancer patients diagnosed during 1995-2011. *Acta Oncol* 55: 611-618, 2016.
110. Ording AG, Nielsen ME, Smith AB, Horváth-Puhó E and Sørensen HT: Venous thromboembolism and effect of comorbidity in bladder cancer: A danish nationwide cohort study of 13,809 patients diagnosed between 1995 and 2011. *Urol Oncol* 34: 292.e1-e8, 2016.
111. Otake S, Ohtsuka T, Asakura K, Kamiyama I and Kohno M: Impact of comorbidity index on morbidity and survival in non-small cell lung cancer. *Asian Cardiovasc Thorac Ann* 24: 30-33, 2016.
112. Parés-Badell O, Banqué M, Macià F, Castells X and Sala M: Impact of comorbidity on survival by tumour location: Breast, colorectal and lung cancer (2000-2014). *Cancer Epidemiol* 49: 66-74, 2017.
113. Pule L, Buckley E, Niyonsenga T, Banham D and Roder D: Developing a comorbidity index for comparing cancer outcomes in Aboriginal and non-Aboriginal Australians. *BMC Health Serv Res* 18: 776, 2018.
114. Pule L, Buckley E, Niyonsenga T and Roder D: Optimizing the measurement of comorbidity for a South Australian colorectal cancer population using administrative data. *J Eval Clin Pract* 26: 1250-1258, 2020.
115. Pule ML, Buckley E, Niyonsenga T and Roder D: The effects of comorbidity on colorectal cancer mortality in an Australian cancer population. *Sci Rep* 9: 8580, 2019.
116. Quante A, Schulz K and Fissler M: Psychiatric comorbidities in cancer patients: Acute interventions by the psychiatric consultation liaison service. *Wien Med Wochenschr* 170: 348-356, 2020.
117. Raghunathan R, Cease K, Troeschel S, Zhao L, Gross M, Chen G, Chopra V and Ramnath N: Impact of staging with positron-emission tomography (PET) and comorbidities on management and survival of american veterans with stage I-III non-small cell lung cancer. *Am J Clin Oncol* 41: 513-518, 2018.
118. Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, Steineck G and Wiklund NP: Effect of comorbidity on prostate cancer-specific mortality: A prospective observational study. *J Clin Oncol* 35: 3566-3574, 2017.
119. Renzi C, Lyratzopoulos G, Hamilton W, Maringe C and Rachet B: Contrasting effects of comorbidities on emergency colon cancer diagnosis: A longitudinal data-linkage study in England. *BMC Health Serv Res* 19: 311, 2019.
120. Rios J, Gosain R, Goulart BH, Huang B, Oechsli MN, McDowell JK, Chen Q, Tucker T and Kloecker GH: Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity. *Cancer Manag Res* 10: 167-175, 2018.
121. Rogers EM, Connolly KL, Nehal KS, Duszka SW, Rossi AM and Lee E: Comorbidity scores associated with limited life expectancy in the very elderly with nonmelanoma skin cancer. *J Am Acad Dermatol* 78: 1119-1124, 2018.
122. Rollet Q, Bouvier V, Launay L, De Mil R, Launoy G, Dejardin O and Alves A: No effect of comorbidities on the association between social deprivation and geographical access to the reference care center in the management of colon cancer. *Dig Liver Dis* 50: 297-304, 2018.
123. Salako O, Okediji PT, Habeebu MY, Fatiregun OA, Awofeso OM, Okunade KS, Odeniyi IA, Salawu KO and Obboh EO: The pattern of comorbidities in cancer patients in Lagos, South-Western Nigeria. *Ecancermedicalscience* 12: 843, 2018.
124. Santorelli ML, Hirshfield KM, Steinberg MB, Lin Y, Rhoads GG, Bandera EV and Demissie K: Racial differences in the effects of comorbidity on breast cancer-specific survival. *Cancer Causes Control* 28: 809-817, 2017.
125. Sarfati D, Gurney J, Lim BT, Bagheri N, Simpson A, Koea J and Dennett E: Identifying important comorbidity among cancer populations using administrative data: Prevalence and impact on survival. *Asia Pac J Clin Oncol* 12: e47-e56, 2016.
126. Seidelin UH, Ibfelt E, Andersen I, Steding-Jessen M, Høgdall C, Kjer SK and Dalton SO: Does stage of cancer, comorbidity or lifestyle factors explain educational differences in survival after endometrial cancer? A cohort study among Danish women diagnosed 2005-2009. *Acta Oncol* 55: 680-685, 2016.
127. Seigneurin A, Delafosse P, Trétarre B, Woronoff AS, Velten M, Grosclaude P, Guizard AV, Lapôtre-Ledoux B, Bara S, Molinié F and Colonna M: Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries. *BMC Cancer* 18: 1091, 2018.
128. Seneviratne S, Campbell I, Scott N, Shirley R, Peni T and Lawrenson R: Ethnic differences in breast cancer survival in New Zealand: Contributions of differences in screening, treatment, tumor biology, demographics and comorbidities. *Cancer Causes Control* 26: 1813-1824, 2015.
129. Shepherd SJ, Creber N, Mansour K, Wiesenfeld D, Iseli TA and Amott D: Relationship between age, comorbidities and complications in head and neck cancer patients undergoing curative surgery. *ANZ J Surg* 90: 851-855, 2020.
130. Skyrud KD, Bray F, Eriksen MT, Nilssen Y and Møller B: Regional variations in cancer survival: Impact of tumour stage, socioeconomic status, comorbidity and type of treatment in Norway. *Int J Cancer* 138: 2190-2200, 2016.
131. Stapelfeldt CM, Duijts SFA, Horsboel TA, Momsen AH, Andersen NT, Larsen FB, Friis K and Nielsen CV: Educational attainment and work disability in cancer survivors: Do diagnosis and comorbidity affect this association? *Eur J Cancer Care (Engl)* 29: e13228, 2020.
132. Stordeur S, Schillemans V, Savoye I, Vanschoenbeek K, Leroy R, Macq G, Verleye L, De Gendt C, Nuyts S, Vermorken J, *et al*: Comorbidity in head and neck cancer: Is it associated with therapeutic delay, post-treatment mortality and survival in a population-based study? *Oral Oncol* 102: 104561, 2020.
133. Swede H, Sarwar A, Magge A, Braithwaite D, Cook LS, Gregorio DI, Jones BA, R Hoag J, Gonsalves L, L Salner A, *et al*: Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis. *Cancer Causes Control* 27: 627-636, 2016.
134. Takemura K, Takenaka Y, Ashida N, Shimizu K, Oya R, Kitamura T, Yamamoto Y and Uno A: Age-adjusted Charlson comorbidity index predicts prognosis of laryngopharyngeal cancer treated with radiation therapy. *Acta Otolaryngol* 137: 1307-1312, 2017.
135. Thielen K, Kolodziejczyk C, Andersen I, Heinesen E and Diderichsen F: Cancer stage, comorbidity, and socioeconomic differences in the effect of cancer on labour market participation: A danish register-based follow-up study. *PLoS One* 10: e0128621, 2015.
136. Tian Y, Jian Z, Xu B and Liu H: Age-adjusted Charlson comorbidity index score as predictor of survival of patients with digestive system cancer who have undergone surgical resection. *Oncotarget* 8: 79453-79461, 2017.
137. Tian Y, Xu B, Yu G, Li Y and Liu H: Comorbidity and the risk of anastomotic leak in Chinese patients with colorectal cancer undergoing colorectal surgery. *Int J Colorectal Dis* 32: 947-953, 2017.
138. Tominaga T, Nonaka T, Takeshita H, Kunizaki M, Sumida Y, Hidaka S, Sawai T and Nagayasu T: The Charlson comorbidity index as an independent prognostic factor in older colorectal cancer patients. *Indian J Surg* 80: 54-60, 2018.
139. Topaloglu US and Özasan E: Comorbidity and polypharmacy in patients with breast cancer. *Breast Cancer* 27: 477-482, 2020.
140. Tran E, Paquette M, Jay J, Hamm J, Liu M, Duncan G, Pickles T and Tyldesley S: The impact of comorbidities on the benefits of prolonged androgen ablation in patients with T3-4 prostate cancer treated with external beam radiation therapy. *Radiother Oncol* 124: 291-295, 2017.
141. Trautmann F, Singer S and Schmitt J: Patients with soft tissue sarcoma comprise a higher probability of comorbidities than cancer-free individuals: A secondary data analysis. *Eur J Cancer Care (Engl)* 26, 2017.
142. Tuzovic M, Yang EH, Sevag Packard RR, Ganz PA, Fonarow GC and Ziaeeian B: National outcomes in hospitalized patients with cancer and comorbid heart failure. *J Card Fail* 25: 516-521, 2019.
143. van Eeghen EE, Bakker SD, van Bochove A and Loffeld RJ: Impact of age and comorbidity on survival in colorectal cancer. *J Gastrointest Oncol* 6: 605-612, 2015.
144. van Walree IC, Hamaker ME, de Rooij BH, Boll D, van Huis-Tanja LH, Emmelot-Vonk MH and Ezendam NPM: Do age and comorbidity impair recovery during two years after treatment for endometrial cancer? *J Geriatr Oncol* 11: 1078-1086, 2020.
145. Vijayvergia N, Li T, Wong YN, Hall MJ, Cohen SJ and Dotan E: Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. *Cancer* 122: 3191-3198, 2016.

146. Walter V, Boakye D, Weberpals J, Jansen L, Haefeli WE, Martens UM, Knebel P, Chang-Claude J, Hoffmeister M and Brenner H: Decreasing use of chemotherapy in older patients with stage III colon cancer irrespective of comorbidities. *J Natl Compr Canc Netw* 17: 1089-1099, 2019.
147. Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK and Daskivich TJ: Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. *Prostate Cancer Prostatic Dis* 22: 252-260, 2019.
148. Williams GR, Deal AM, Lund JL, Chang Y, Muss HB, Pergolotti M, Guerard EJ, Shachar SS, Wang Y, Kenzik K and Sanoff HK: Patient-reported comorbidity and survival in older adults with cancer. *Oncologist* 23: 433-439, 2018.
149. Woelfel IA, Fernandez LJ, Idowu MO and Takabe K: A high burden of comorbid conditions leads to decreased survival in breast cancer. *Gland Surg* 7: 216-227, 2018.
150. Wollschläger D, Meng X, Wöckel A, Janni W, Kreienberg R, Blettner M and Schwentner L: Comorbidity-dependent adherence to guidelines and survival in breast cancer-is there a role for guideline adherence in comorbid breast cancer patients A retrospective cohort study with 2137 patients. *Breast J* 24: 120-127, 2018.
151. Wong ML, McMurry TL, Schumacher JR, Hu CY, Stukenborg GJ, Francescatti AB, Greenberg CC, Chang GJ, McKellar DP, Walter LC and Kozower BD: Comorbidity assessment in the national cancer database for patients with surgically resected breast, colorectal, or lung cancer (AFT-01, -02, -03). *J Oncol Pract* 14: e631-e643, 2018.
152. Wong ML, McMurry TL, Stukenborg GJ, Francescatti AB, Amato-Martz C, Schumacher JR, Chang GJ, Greenberg CC, Winchester DP, McKellar DP, *et al*: Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study. *Lung Cancer* 102: 108-117, 2016.
153. Wu SY, Fang SC, Hwang OR, Shih HJ and Shao YJ: Influence of baseline cardiovascular comorbidities on mortality after androgen deprivation therapy for metastatic prostate cancer. *Cancers (Basel)* 12: 189, 2020.
154. Yamano T, Yamauchi S, Kimura K, Babaya A, Hamanaka M, Kobayashi M, Fukumoto M, Tsukamoto K, Noda M, Tomita N, *et al*: Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study. *Eur J Cancer* 81: 90-101, 2017.
155. Yoon SJ, Kim EJ, Seo HJ and Oh IH: The association between Charlson comorbidity index and the medical care cost of cancer: A retrospective study. *Biomed Res Int* 2015: 259341, 2015.
156. Yutaka Y, Sonobe M, Kawaguchi A, Hamaji M, Nakajima D, Ohsumi A, Menju T, Chen-Yoshikawa TF, Sato T and Date H: Prognostic impact of preoperative comorbidities in geriatric patients with early-stage lung cancer: Significance of sublobar resection as a compromise procedure. *Lung Cancer* 125: 192-197, 2018.
157. Zhao L, Leung LH, Wang J, Li H, Che J, Liu L, Yao X and Cao B: Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. *BMC Pulm Med* 17: 112, 2017.
158. Zist A, Amir E, Ocana AF and Seruga B: Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel. *Radiol Oncol* 49: 402-408, 2015.